Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Conoravirus Disease Portal

COVID-19 GPH|Home|PHGKB Last data update: Oct 19, 2020 . (Total: 12545 Documents since 2020)

Last Posted: Oct-19-2020 12:33:39
spot light Spotlight

Suicide Prevention in the COVID-19 Era- Transforming Threat Into Opportunity
C Moutier, JAMA Psychiatry, October 16, 2020

COVID-19 presents a new and urgent opportunity to focus political will, federal investments, and global community on the vital imperative of suicide prevention. Suicide prevention in the COVID-19 era requires addressing not only pandemic-specific suicide risk factors, but also prepandemic risk factors. This paper provides prioritized, evidence-based strategies along with national and local policy and educational initiatives tailored to the COVID-19 environment.

Individuals with Down syndrome hospitalized with COVID-19 have more severe disease
L Malle et al, Genetics in Medicine, October 18, 2020

In this retrospective study of 7246 patients hospitalized with COVID-19, we identified 12 patients with DS. Hospitalized individuals with DS are on average ten years younger than patients without DS. Patients with DS have more severe disease than controls, particularly an increased incidence of sepsis and mechanical ventilation.

Race, Ethnicity, and Age Trends in Persons Who Died from COVID-19 — United States, May–August 2020
JAW Gold et al, CDC MMWR, October 16, 2020

Analysis of 114,411 COVID-19–associated deaths reported to National Vital Statistics System during May–August 2020, found that 51.3% of decedents were non-Hispanic White, 24.2% were Hispanic or Latino (Hispanic), and 18.7% were non-Hispanic Black. The percentage of Hispanic decedents increased from 16.3% in May to 26.4% in August.

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
WHO Solidarity Trial Consortium, MEDRXIV, October 15, 2020

Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. The mortality findings contain most of the randomized evidence on Remdesivir and Interferon, and are consistent with meta-analyses of mortality in all major trials.

news Latest News and Publications
COVID-19, Social Justice, and Clinical Cancer Research
JH Doroshow et al, JNCI, October 15, 2020

New Added Today

Analysis of respiratory and systemic immune responses in COVID-19 reveals mechanisms of disease pathogenesis
PA Szabo et al, MEDRXIV, October 19, 2020

New Added Today

Superspreading Event of SARS-CoV-2 Infection at a Bar, Ho Chi Minh City, Vietnam
Chau NV, et al. Emerg Infect Dis, Oct 15, 2020.

New Added Today

Considerations for diagnostic COVID-19 tests
Vandenberg O, et al. Nat Rev Microbiol, Oct 14, 2020.

New Added Today

Older People No More Susceptible to COVID-19, But Fare Worse
D MacNamara, MEDSCAPE, October 15, 2020

New Added Today

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
DE Leisman et al, Lancet Resp Med, October 16, 2020

New Added Today

All Latest

Sign up Email Alert

Content Statistics

  • Total (12545)
  • Genomics Precision Health (9396)
  • Non-Genomics Precision Health (2502)

About COVID-19 GPH

COVID-19 GPH is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that captures emerging discoveries and applications of genomics, molecular and other precision medicine and precision public health tools in the investigation and control of COVID-19. Contents include PubMed records via an automated pubmed search algorithm, preprint records from NIH iCite, the relevant information from many media sources picked by experts, and linkages to contents from our curated PHGKB databases.

Genomics Precision Health: The use of pathogen and human genomics and advanced molecular detection methods in discovery, clinical and public health investigations involving COVID-19.
Non Genomics Precision Health: The use of big data, data science and machine learning methods (not involving genomics) in discovery, clinical and public health investigations involving COVID-19

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.